Reproductive Solutions Reports ProteX Sperm Collection Solution Offers New Hope for Infertile Couples

Yields Better Specimen Quality for Fertility Clinic Use & Extends Sperm Viability to 48 Hours

Reproductive Solutions notes in a breakthrough for collecting sperm samples for fertility treatment, Reproductive Solutions (RSI) today announced the availability of a patented, FDA-listed semen collection container that improves specimen quality for in vitro fertilization and other assisted reproductive technologies.

Reproductive Solutions advises The ProteX™ container also preserves a high-quality sample for up to 48 hours compared to the 45 to 60 minutes of standard 50-year-old collection methods, enabling at-home collection while also easing bottlenecks at fertility clinic labs.

Unlike urine specimen cups traditionally used for semen collection, ProteX features an insulated design and an interior funnel that directs sperm to a small holding well that combine to prevent severe temperature fluctuations and minimize the surface area exposed to the environment. These and other features reduce damage to semen quality, resulting in increased motility, sperm count and fertilization capability.

Developed by reproductive health specialists at Texas Tech University and studied extensively before market introduction, the ProteX solution has been proven to:

  • Protect sperm from thermal shock, pH imbalance and osmotic stress that cause cellular damage to sperm at the time of collection

  • Slow sperm cooling rate to just 0.5° F per minute compared to a loss of 30° F measured in standard specimen cups in the first 10 minutes alone

  • Provide up to 50% higher sperm motility than the generic specimen cup, in which sperm samples have a declining motility rate from the moment of collection

  • Increase the likelihood of egg fertilization by keeping sperm acrosomes up to 45% more intact than a standard specimen cup at 24 hours, with an even higher percentage of intact acrosomes at 1, 3, 6, 12 and 18 hours

  • Keep sperm samples stable at the highest possible motility for up to 48 hours, allowing men to collect at home and deliver the sample to the clinic within the 48-hour window versus the 1-hour standard

For men and their partners, ProteX also eliminates the pressure of producing a sample at a clinic and thereby helps improve the viability of the sample. Studies show the stress hormone cortisol, which is released in the body as a chemical expression of psychosocial stress, negatively impacts progressive motility and sperm count.

For fertility clinics, ProteX eliminates the need for collection rooms, increases the number of patients who can be treated, and simplifies lab scheduling by extending sample viability to up to 48 hours rather than requiring processing within 45-60 minutes.

“Roughly 40% of infertility problems can be traced to the male partner, yet there has been little focus on improving the male side of the fertility equation in the clinical work,” said Diana Peninger, President and CEO of Reproductive Solutions. “As the first advance in semen collection, our ProteX container not only allows samples to be collected at home without compromising quality but also provides a healthier specimen with the potential to increase the odds of conception. This is a significant development for couples as well as clinics.”

The ProteX solution is currently in use at several fertility clinics and will be available directly to consumers this spring.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version